Arca
Skip to content
Tools
Tools

Asparagine

Small molecule in Homo sapiens that 5 drugs act on.

  • Drugs that act on it: 5
  • Approved: 5
  • In phases 1 to 3: 0
  • Sponsors: 5

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 5

Approved5

  • Asparaginase
  • Pegaspargase
  • Calaspargase pegol
  • Asparaginase erwinia chrysanthemi
  • Crisantaspase

Phase 30

    Phase 20

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Asparagine hydrolytic enzyme.
        AsparaginaseApprovedMerck & Co. (MSD)Protein or peptideHydrolytic enzyme70
        PegaspargaseApprovedSigma-TauProtein or peptideHydrolytic enzyme64
        Calaspargase pegolApprovedServierProtein or peptideHydrolytic enzyme22
        Asparaginase erwinia chrysanthemiApprovedJazz PharmaceuticalsProtein or peptideHydrolytic enzyme17
        CrisantaspaseApprovedPfizerProtein or peptideHydrolytic enzyme17

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 27 in all, from ClinicalTrials.gov.
        GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell LymphomaPegaspargasePhase 2Not yet recruitingFudan UniversityAug 17, 2026
        BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCLPegaspargasePhase 3RecruitingRong TaoJul 1, 2026
        Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentAsparaginase, Calaspargase pegolPhase 2Not yet recruitingSWOG Cancer Research NetworkJun 9, 2026
        A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer PatientsAsparaginasePhase 4RecruitingHongxia WangMay 11, 2026
        A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell LymphomaPegaspargasePhase 2Not yet recruitingSun Yat-sen UniversityMay 8, 2026
        Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell LymphomaAsparaginase, PegaspargasePhase 2Not yet recruitingBeijing Tongren HospitalApr 28, 2026
        Role of T Lymphocytes in Hypersensitivity Reactions to Asparaginase in Patients Treated for Acute Lymphoblastic Leukemia.AsparaginaseNot applicableNot yet recruitingCentre Hospitalier Universitaire de NiceApr 14, 2026
        Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)Asparaginase, PegaspargasePhase 1 / Phase 2RecruitingBeijing Tongren HospitalApr 13, 2026
        UNDERSTANDING THE T-CELL AND B-CELL RECEPTOR REPERTOIRE IN CHILDREN AND YOUNG ADULTS WITH ANTI-DRUG ANTIBODIES AGAINST PEG ASPARAGINASEAsparaginase, Pegaspargase—Not yet recruitingAarhus University HospitalMar 30, 2026
        Establishment of a Phamacokinetik Model for Erwinase Pharmacokinetiks: The Aim of This Sub Study is to Optimize Target Trough Attainment While Minimizing High Exposures That Impose Increased Risk of Side Effects Such as HyperammonemiaAsparaginase—RecruitingAarhus University HospitalMar 30, 2026
        Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic LeukemiaPegaspargaseNot applicableRecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaMar 27, 2026
        Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTLPegaspargasePhase 2Not yet recruitingLIANG WANGMar 9, 2026
        A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLCAsparaginaseNot applicableNot yet recruitingFudan UniversityFeb 18, 2026
        Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol AdministrationCalaspargase pegol—Not yet recruitingMayo ClinicOct 28, 2025
        Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaAsparaginase erwinia chrysanthemi, CrisantaspasePhase 1RecruitingCity of Hope Medical CenterAug 21, 2025
        Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Calaspargase pegolPhase 2 / Phase 3Not yet recruitingChildren's Oncology GroupJul 18, 2025
        Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot StudyCalaspargase pegol—RecruitingMayo ClinicJul 17, 2025
        UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AMLAsparaginase erwinia chrysanthemi, CrisantaspaseEarly phase 1RecruitingBaylor College of MedicineJul 11, 2025
        Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaAsparaginase erwinia chrysanthemi, CrisantaspasePhase 2RecruitingCity of Hope Medical CenterApr 9, 2025
        A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia AsparaginaseAsparaginase erwinia chrysanthemi, Crisantaspase—RecruitingMayo ClinicSep 19, 2024
        A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)Calaspargase pegolPhase 2RecruitingM.D. Anderson Cancer CenterAug 19, 2024
        Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and LymphomaCalaspargase pegolPhase 2RecruitingSt. Jude Children's Research HospitalAug 1, 2024
        Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)Calaspargase pegolPhase 2RecruitingSt. Jude Children's Research HospitalApr 30, 2024
        Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaAsparaginase erwinia chrysanthemi, Calaspargase pegol, CrisantaspasePhase 2RecruitingNational Cancer Institute (NCI)Mar 19, 2024
        A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLAsparaginase erwinia chrysanthemi, CrisantaspasePhase 2RecruitingPfizerFeb 28, 2023
        Venetoclax Basket Trial for High Risk Hematologic MalignanciesAsparaginase erwinia chrysanthemi, CrisantaspasePhase 1Active, not recruitingAndrew E. Place, MDMar 23, 2022
        Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and NavitoclaxAsparaginase erwinia chrysanthemi, CrisantaspasePhase 1 / Phase 2Active, not recruitingSt. Jude Children's Research HospitalJan 14, 2022

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364706, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.